Paper880258
Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.
Müller WE and 3 others. Biochem Pharmacol, 1977. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. Papers, record 880258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/880258
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Division | Major topic |
| Ribavirin | Major topic |
| Ribonucleosides | Major topic |
| Cells, Cultured | |
| DNA | |
| DNA-Directed DNA Polymerase | |
| DNA-Directed RNA Polymerases | |
| Depression, Chemical | |
| Drug Interactions | |
| Guanosine Triphosphate | |
| Polyribosomes | |
| Protein Biosynthesis | |
| RNA |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37623252 | Recent Advances in Molecular Mechanisms of Nucleoside Antivirals. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/37623252 | PubMed |
| 36602354 | Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/36602354 | PubMed |
| 36358961 | Hydrophobic Rose Bengal Derivatives Exhibit Submicromolar-to-Subnanomolar Activity against Enveloped Viruses. | Biomolecules | 2022 | https://conductscience.org/library/papers/36358961 | PubMed |
| 36297288 | Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36297288 | PubMed |
| 34955556 | Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action. | Mol Biol | 2021 | https://conductscience.org/library/papers/34955556 | PubMed |
| 34765999 | Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. | Mol Biomed | 2020 | https://conductscience.org/library/papers/34765999 | PubMed |
| 33924302 | Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. | Viruses | 2021 | https://conductscience.org/library/papers/33924302 | PubMed |
| 33623816 | Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2. | Inform Med Unlocked | 2021 | https://conductscience.org/library/papers/33623816 | PubMed |
| 28359770 | Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties. | J Virol Methods | 2017 | https://conductscience.org/library/papers/28359770 | PubMed |
| 27754363 | Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations. | Viruses | 2016 | https://conductscience.org/library/papers/27754363 | PubMed |
| 26222794 | Ribavirin Inhibits Parrot Bornavirus 4 Replication in Cell Culture. | PLoS One | 2015 | https://conductscience.org/library/papers/26222794 | PubMed |
| 22495651 | Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. | Med Res Rev | 2012 | https://conductscience.org/library/papers/22495651 | PubMed |
| 19643775 | Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. | J Antimicrob Chemother | 2009 | https://conductscience.org/library/papers/19643775 | PubMed |
| 19244331 | Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. | J Virol | 2009 | https://conductscience.org/library/papers/19244331 | PubMed |
| 17855555 | Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. | J Virol | 2007 | https://conductscience.org/library/papers/17855555 | PubMed |
| 17060520 | Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17060520 | PubMed |
| 16287208 | Mechanisms of action of ribavirin against distinct viruses. | Rev Med Virol | 2006 | https://conductscience.org/library/papers/16287208 | PubMed |
| 16131589 | The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. | RNA | 2005 | https://conductscience.org/library/papers/16131589 | PubMed |
| 16043507 | Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. | RNA | 2005 | https://conductscience.org/library/papers/16043507 | PubMed |
| 15911031 | Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. | Antiviral Res | 2005 | https://conductscience.org/library/papers/15911031 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/880258
GET https://conductscience.org/api/papers/v1/880258/cited_by?page=2